Home / Top News / EBON INVESTOR DEADLINE: HAGENS BERMAN, National Trial Attorneys, Encourages Ebang International Holdings (EBON) Investors with Losses to Contact Its Attorneys Now, Securities Class Action Filed
EBON INVESTOR DEADLINE: HAGENS BERMAN, National Trial Attorneys, Encourages Ebang International Holdings (EBON) Investors with Losses to Contact Its Attorneys Now, Securities Class Action Filed
SAN FRANCISCO, May 08, 2021 (GLOBE NEWSWIRE) Hagens Berman urges Ebang International Holdings (
NASDAQ: EBON) investors with significant losses to submit your losses now. The firm is investigating possible securities fraud and certain investors may have valuable claims.
Class Period: June 26, 2020 – Apr. 5, 2021
Lead Plaintiff Deadline: June 7, 2021
Visit: www.hbsslaw.com/investor-fraud/EBON
Ebang International Holdings (NASDAQ: EBON) Securities Class Action:
The investigation focuses on the accuracy of Ebang’s statements concerning its use of capital raised from investors and its claim to be a leading manufacturer of bitcoin mining machines.
More specifically, over the past year, Ebang raised approximately $374 million from investors in public offerings and represented it would use these proceeds to “further expand our operations” in cryptocurrency mining, exchange platforms, and general corporate purposes.
These statements were brought into question on Apr. 6, 2021, when analyst
Hindenburg Research published a scathing report entitled “Ebang: Yet Another Crypto ‘China Hustle’ Absconding With U.S. Investor Cash.”
Athenex, Inc. (NASDAQ: ATNX) Securities Class Action:
The Complaint alleges that throughout the Class Period, Defendants made false statements and omissions about its flagship drug candidate, an oral paclitaxel and encequidar for the treatment of metastatic breast cancer.
Specifically, Defendants misrepresented and concealed that: (i) the data included in the Oral Paclitaxel plus Encequidar New Drug Application presented a safety risk to patients; (ii) there was uncertainty over the results of the primary endpoint of objective response rate (ORR), which might have introduced unmeasured bias and influence on the blinded independent central review (BICR); (iii) the Company’s Phase 3 study did not include a representative population; and (iv) as a result, it was foreseeable that the FDA would not approve the Company’s NDA in its current form.
Home / Top News / ATNX DEADLINE MONDAY: HAGENS BERMAN, National Trial Attorneys, Alerts Athenex (ATNX) Investors to May 3rd Application Deadline in Securities Class Action, Advises Investors with Losses to Contact the Firm Immediately
ATNX DEADLINE MONDAY: HAGENS BERMAN, National Trial Attorneys, Alerts Athenex (ATNX) Investors to May 3rd Application Deadline in Securities Class Action, Advises Investors with Losses to Contact the Firm Immediately
SAN FRANCISCO, May 01, 2021 (GLOBE NEWSWIRE) Hagens Berman urges Athenex, Inc.
(NASDAQ: ATNX) investors with significant losses to submit your losses now.
Class Period: Aug. 7, 2019 – Feb. 26, 2021
Lead Plaintiff Deadline: May 3, 2021 Visit: www.hbsslaw.com/investor-fraud/atnx
Athenex, Inc. (NASDAQ: ATNX) Securities Class Action:
Home / Top News / ATNX 2-WEEK DEADLINE ALERT: HAGENS BERMAN Urges Athenex (ATNX) Investors with Losses to Contact Its Attorneys, Securities Class Action Deadline Approaching
ATNX 2-WEEK DEADLINE ALERT: HAGENS BERMAN Urges Athenex (ATNX) Investors with Losses to Contact Its Attorneys, Securities Class Action Deadline Approaching
SAN FRANCISCO, April 19, 2021 (GLOBE NEWSWIRE) Hagens Berman urges Athenex, Inc.
(NASDAQ: ATNX) investors with significant losses to submit your losses now.
Class Period: Aug. 7, 2019 – Feb. 26, 2021
Lead Plaintiff Deadline: May 3, 2021
Visit: www.hbsslaw.com/investor-fraud/ATNX
Athenex, Inc. (NASDAQ: ATNX) Securities Class Action:
The Complaint alleges that throughout the Class Period, Defendants made false statements and omissions about its flagship drug candidate, an oral paclitaxel and encequidar for the treatment of metastatic breast cancer.